Gyre Therapeutics Inc
NASDAQ:GYRE

Watchlist Manager
Gyre Therapeutics Inc Logo
Gyre Therapeutics Inc
NASDAQ:GYRE
Watchlist
Price: 7.98 USD 1.01% Market Closed
Market Cap: $725.3m

Net Margin

6.2%
Current
Improving
by 144.6%
vs 3-y average of -138.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
6.2%
=
Net Income
$6.7m
/
Revenue
$107.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
6.2%
=
Net Income
$6.7m
/
Revenue
$107.3m

Peer Comparison

Country Company Market Cap Net
Margin
US
Gyre Therapeutics Inc
NASDAQ:GYRE
718m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
58th
Based on 15 072 companies
58th percentile
6.2%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Gyre Therapeutics Inc
Glance View

Gyre Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2006-04-12. Gyre Therapeutics, Inc., formerly Catalyst Biosciences, Inc., is a biotechnology company. The firm is focused on organ fibrosis and inflammatory diseases. The firm is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The firm is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase 3 trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase 1 trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.

GYRE Intrinsic Value
25.68 USD
Undervaluation 69%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
6.2%
=
Net Income
$6.7m
/
Revenue
$107.3m
What is Gyre Therapeutics Inc's current Net Margin?

The current Net Margin for Gyre Therapeutics Inc is 6.2%, which is above its 3-year median of -138.4%.

How has Net Margin changed over time?

Over the last 3 years, Gyre Therapeutics Inc’s Net Margin has decreased from 367.8% to 6.2%. During this period, it reached a low of -1 043% on Dec 31, 2022 and a high of 367.8% on Sep 30, 2022.

Back to Top